Score mapped
Interactive worksheet
Clinical inputs
0/5 filled
Clinical contextWhy this tool matters and how to interpret it
Understand the result,
not just the number.
Appraisal of Risk in AF (ARISTOTLE-based) Score: Explanation and Clinical Context The ARISTOTLE-based risk score for atrial fibrillation was developed from the ARISTOTLE trial population to predict 1-year risk of stroke or systemic embolism in patients with AF. The model is based on easily obtainable clinical variables including age, prior stroke or transient ischemic attack (TIA), hypertension, diabetes mellitus, and heart failure or reduced left ventricular ejection fraction. The score uses a weighted linear model derived from Cox proportional hazards regression in the ARISTOTLE trial, allowing estimation of individualized 1-year stroke risk.
Predicted risk is categorized as low (<1.5%), intermediate (1.5–3.0%), and high (>3.0%), supporting decision-making for anticoagulation therapy. This tool provides a more precise alternative to traditional risk scores such as CHA₂DS₂-VASc, by reflecting empirically derived hazard ratios in a contemporary trial population treated with anticoagulants.
Evidence & references1 primary source mapped
- Source 1
Patel MR, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. Hijazi Z, et al. Biomarker-based risk scores for predicting stroke and bleeding in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2016;37:1230–1237. Wallentin L, et al. Application of ABC-AF stroke and bleeding risk scores in contemporary clinical practice. Thromb Haemost. 2020;120:748–756.
Clinical discussionModerated, tool-specific conversation
Loading discussion…